BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - NYSE:BIO - US0905722072 - Common Stock
310.35 USD
-1.08 (-0.35%)
We assign a fundamental rating of 4 out of 10 to BIO. BIO was compared to 58 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
In the past year BIO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
Each year in the past 5 years BIO had a positive operating cash flow.
1.2 Ratios
BIO's Return On Assets of -6.97% is in line compared to the rest of the industry. BIO outperforms 51.72% of its industry peers.
Looking at the Return On Equity, with a value of -10.03%, BIO is in line with its industry, outperforming 53.45% of the companies in the same industry.
BIO has a Return On Invested Capital of 2.26%. This is in the better half of the industry: BIO outperforms 60.34% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 13.50%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
The Operating Margin of BIO (10.27%) is better than 68.97% of its industry peers.
BIO's Operating Margin has been stable in the last couple of years.
With a Gross Margin value of 52.42%, BIO perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
Compared to 5 years ago, BIO has less shares outstanding
Compared to 1 year ago, BIO has a worse debt to assets ratio.
2.2 Solvency
BIO has an Altman-Z score of 3.43. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.43, BIO is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
BIO has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO would need 3.57 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.57, BIO is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
BIO has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO outperforms 56.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.43 |
ROIC/WACC0.22
WACC10.29%
2.3 Liquidity
BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.44, BIO is doing good in the industry, outperforming 75.86% of the companies in the same industry.
BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BIO (3.94) is better than 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -1.90% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
Looking at the last year, BIO shows a decrease in Revenue. The Revenue has decreased by -0.88% in the last year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
Based on estimates for the next years, BIO will show a decrease in Earnings Per Share. The EPS will decrease by -2.55% on average per year.
Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 1.48% on average per year.
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.55%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.48%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.10, the valuation of BIO can be described as expensive.
BIO's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 68.97% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 29.74, the valuation of BIO can be described as expensive.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 70.69% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.53, BIO is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.1 | ||
| Fwd PE | 29.74 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO is valued a bit cheaper than the industry average as 79.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.94 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.84
EPS Next 2Y0.61%
EPS Next 3Y4.05%
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO (11/4/2025, 1:35:26 PM)
310.35
-1.08 (-0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.73%
Inst Owner Change-0.22%
Ins Owners3.84%
Ins Owner Change0%
Market Cap8.40B
Revenue(TTM)2.56B
Net Income(TTM)-675902000
Analysts76
Price Target317.22 (2.21%)
Short Float %6.08%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-4.99%
PT rev (3m)-1.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.81%
EPS NY rev (1m)-0.92%
EPS NY rev (3m)13.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.1 | ||
| Fwd PE | 29.74 | ||
| P/S | 3.28 | ||
| P/FCF | 24.94 | ||
| P/OCF | 17.09 | ||
| P/B | 1.25 | ||
| P/tB | 1.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.32%
EPS(NY)10.44
Fwd EY3.36%
FCF(TTM)12.44
FCFY4.01%
OCF(TTM)18.16
OCFY5.85%
SpS94.51
BVpS248.96
TBVpS213.22
PEG (NY)N/A
PEG (5Y)3.84
Graham Number240.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.43 |
F-Score5
WACC10.29%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.55%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.48%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.54%
EBIT Next 3Y15.21%
EBIT Next 5Y7.17%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
What is the valuation status of BIO-RAD LABORATORIES-A (BIO) stock?
ChartMill assigns a valuation rating of 2 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
What are the PE and PB ratios of BIO-RAD LABORATORIES-A (BIO) stock?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES-A (BIO) is 30.1 and the Price/Book (PB) ratio is 1.25.
What is the expected EPS growth for BIO-RAD LABORATORIES-A (BIO) stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -1.6% in the next year.